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INTRODUCTION:
The concept of prostate tumor development as a multi-step process has been well documented. Analysis of human prostate cancer specimens has revealed a variety of deviant tissue states, from early carcinomas and highly malignant tissue, to invasive carcinoma and distant metastases. The many steps of prostate cancer tumor progression are evident from the accumulation of mutant genes in cells as they evolve from a benign state to a malignant state. The loss of PTEN (chromosome 10q), pRB (chromosome 13q) and p53 (chromosome 17p) is coupled with a large percentage of tumors harboring Myc amplifications, AR mutations and Bcl-2 overexpression [1] [2] [3] . In agreement with this, our data indicate a stage or metastasis-dependent loss of PTPsigma (PTPRS) mRNA. These data suggest that PTPsigma may be involved in prostate progression, perhaps through activation of autophagy after loss of PTPsigma.
BODY:
Aim #1: Identify the catalytic mechanism whereby PTPRS regulates PI(3)P levels. We have completed the following tasks associated with the Statement of Work. Figures referenced for all tasks include unpublished data (Figures 1-3 in the Supplementary Data) as well as those published within the article attached in Supplementary Data [4] . We have generated PTPRS constructs containing catalytically inactive point mutations in the D1 (C1589S and C1589A), D2 (C1880S), and both D1 and D2 PTP domains (task 1) (Fig. 1A) . These mutations have been sequence-verified and characterized for phosphatase activity in vitro (task 2). The constructs have been inserted in bacterial vectors (pGEXKG) for recombinant protein purification as well as mammalian expression vectors (PTPRS in full-length and a truncated form containing the transmembrane and cytosolic residues). We measured PTPRS activity using a phospho-tyrosine (pTyr) peptide with malachite green free phosphate detection to verify catalytic activity residues exclusively within the D1 domain (Fig. 1B) . We cannot detect robust PI(3)P-phosphatase activity using standard assays ( Fig. S3 [4 
]).
We have also completed the autophagy assays that include LC3 Western blots (task 4) and immunofluorescence for endogenous LC3 (task 5) (Figs. 1, 2, S2 [4] ). We have monitored autophagic vesicles by electron microscopy (task 6) at the Michigan State University Center for Advanced Microscopy (Fig. 3 [4] ). We have also quantified the number of autophagic vesicles per cell for both cells containing wild-type PTPRS and those subjected to siRNA-mediated knockdown of PTPRS (task 7) (Figs. 2, S2 [4] ). This work is described in more detail within the attached referenced article. For this Aim, the remaining task (task 3) includes testing the mutants in C4-2B cells to determine the necessity of the active site in prostate cancer cells, as compared to immortalized normal PEC36 prostate cells. We have measured autophagy in a panel of metastatic prostate cancer cell lines as preliminary effort to this goal (Fig. 2) . Aim #2: Determine the regulation and subcellular localization of PTPRS during autophagy. We have completed the following tasks associated with the Statement of Work. We have cloned and expressed full-length, untagged PTPRS which we detect by standard immunoblotting protocols using a D1-targeted (C-terminal) monoclonal antibody (task 1). This is a refinement of the original approach which involved a C-terminal V5 epitope tag. We have analyzed PTPRS processing in U2OS cells where we found that a C-terminal fragment (CTF) is constitutively turned over in the lysosome in the presence of full-nutrients (Fig. 3A) . The formation of this CTF is blocked by Batimastat, an extracellular metalloprotease inhibitor, suggesting it is generated following cleavage (Fig. 3B) . Upon autophagy induction (by amino acid starvation), a further processed fragment is formed which we predict is an intracellular domain (ICD) (Fig.  3C) .
We have performed numerous autophagy assays (task 2, task 3, task 4) ( Fig. 2; Figs. 1-3 , S2 [4] ). We have monitored PTPRS localization using standard immunofluorescence microscopy. We have introduced full-length, untagged PTPRS into U2OS cells and followed the C-terminus using D1-targeted monoclonal antibodies (task 5). Again, this is a refinement of the original approach using C-terminal V5-tagged PTPRS. We have compared PTPRS distribution to both EGFP-2xFYVE and RFP-labeled LC3 to find PTPRS on both PI(3)P and LC3-positive vesicles (task 6) (Figs. 4, 5, S3 [4] ). We have assessed the enrichment of PTPRS in an autophagic fraction during autophagy by comparing cells cultured in full nutrients to those starved of amino acids (task 8) . For this Aim, several tasks remain to be completed. One task includes the isolation of autophagosomes by differential centrifugation from cells (task 7). A published protocol has been identified and pilot studies are underway. Further, immunogold electron microscopy can be utilized to further define the subcellular localization of PTPRS (task 9, task 10). We have established a relationship with the transmission electron microscopy core at Michigan State University Center for Advanced Microscopy and are familiar with protocols to accomplish these tasks.
Specific Aim #3: Establish the role of PTPRS in prostate cancer chemoresistance.
In this Aim, we will evaluate the role of PTPRS in prostate cancer chemoresistance using an androgen-independent C4-2B metastatic model of prostate cancer. We will generate stable C4-2B cell lines expressing EGFP (task 1). CB17 SCID will be injected with EGFP-positive C4-2B cells into the prostate gland (task 2). Tumors will be allowed to grow for 10 weeks, at which time the mice will be randomly assigned to one of four groups of ten mice. Each group of mice will then be treated by intraperitoneal injection with control, docetaxel (low dose, 10 mg/kg) or docetaxel (high dose, 60 mg/kg), respectively (task 3). Animal health will be monitored daily (task 4). Injections will continue every week for three weeks (injections on days 1, 7, 14, and 21 for a total of 4 injections) at which time the mice will be euthanized and the tumors will be dissected (task 5). Half of each tumor will be paraffin embedded, and half of the tumor will be frozen for later analysis (task 6). Lungs will be excised, fixed, and lung metastasis quantified (task 7). We will measure 25 sections (20 μm thick) from the apex to the base of the lung for the presence of metastasis. The general strategy of the PTPRS C to S mutant experimental approach is to inject stable clones expressing high levels of PTPRS or PTPRS C1589S or C1880S (task 8) . Injected cells will then be allowed to establish tumors for 10 weeks. Established tumors will then be treated by intraperitoneal injection of docetaxel (task 9). Tumors will also be treated with vehicle control as a negative control. Immunohistochemistry and western blot (anti-V5 antibody) for V5-PTPRS will be used to confirm expression levels (task 10) . To drive refinement of the model, pilot studies have been designed. Protocols for these tasks have been submitted to the IACUC committee at VAI and have been approved. Kinetics of both autophagymodulating compounds (rapamycin, chloroquine, bafilomycin A1) and chemotherapeutics (taxol, cisplatin, etoposide) have been investigated in a number of metastatic prostate cancer lines in vitro (including LNCaP, C4-2B, DU145, and PC3) ( Table 1) .
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After successful completion of the orthotopic lung metastatic model, we will use the C4-2B-EGFP cells and intratibial inoculation to quantify tumor burden in a metastatic relevant site after systemic chemotherapy (task 11) . Tumor burden will be quantified on days 10, 17, and 24 after injection of the tumor cells (task 12) . Whole body fluorescent images will be obtained using our whole animal bioluminescence equipment in the injected tibiae. Again, mice injected intratibial with either wild-type PTPRS or the C to S mutant; and mice will be treated with docetaxel as described above (task 13). The immunohistochemistry staining will be performed (task 14) . One section from each prostate tumor and lung metastases will be stained, scanned, and digital images obtained for proliferation (PCNA, Ki67) and apoptosis (activated caspase 9). Protocols have been written, submitted, and approved for this work. Optimization of this technique and pilot studies are underway.
KEY RESEARCH ACCOMPLISHMENTS:
• RNAi screen identifies PTPsigma as a modulator of PI(3)P signaling • Loss of PTPsigma hyperactivates constitutive and induced autophagy • PTPsigma localizes to PI(3)P-positive vesicles and rescues the siRNA phenotype • The vesicular localization of PTPsigma does not require PI(3)P • PTPsigma harbors robust protein tyrosine phosphatase activity, but not PI(3)Pphosphatase activity, and this is harbored within the D1 PTP domain • PTPsigma is processed into a CTF during constitutive autophagy and targeted to the lysosome • PTPsigma is processed into a putative ICD during starvation-induced autophagy 
CONCLUSION:
Through use of a high-content cell-based RNAi screen, we have identified phosphatases whose knockdown elevates cellular PI(3)P. Notably, RNAi-mediated knockdown of MTMR6 and several other phosphatases resulted in swollen and often perinuclear PI(3)P-positive vesicles. Previous studies have shown similar phenotypes when endocytic PI(3)P is elevated, for example, by constitutive activation of early endosomal Rab5, or knockdown of the PI5-kinase, PIKfyve [5, 6] . Accordingly, the vesicles observed following knockdown of these phosphatases are likely endosomal and these enzymes, including MTMR6, may function in endocytic signaling. Of note, knockdown of both PTPN11 (SHP2) and PTPN13 (PTPL1) resulted in increased EGFP-2xFYVE punctae ( Table 2 .1). PTPN13, a phosphatase proposed to have both tumor suppressive and oncogenic functions, has been implicated in several signal transduction pathways. Specifically, PTPN13 was shown to inhibit PI3K/Akt signaling and thus, the PI(3)P phenotype elicited by knockdown could potentially be explained by altered 3'-phosphoinositide metabolism [7, 8] . Mutations in SHP2 are associated with several human diseases, most notably Noonan syndrome, LEOPARD syndrome, and juvenile myelomonocytic leukemia [9] [10] [11] [12] . Its activity has been linked to numerous signaling pathways, often downstream of receptor tyrosine kinases, and the observed phenotype could be a consequence of disruption of any number of substrates [13] . Surprisingly, we did not identify MTMR3 or MTMR14 (hJumpy), the PI(3)P-phosphatases with reported roles in autophagy. The myotubularin phosphatases comprise a large, highly conserved family of enzymes whose members have been shown to function as heteromeric partners [14] . As one example, MTMR3 and MTMR4, both FYVE-domain containing phosphatases, have been demonstrated to interact and inhibit PI(3)P [14] . Accordingly, gene-by-gene loss of function analysis of this family may not reveal phenotypes if compensation within the family occurs. Further, these enzymes may serve cell-or context-specific functions not revealed in this study.
The most striking result from this study was the presence of abundant PI(3)P-positive vesicles following PTPsigma knockdown which phenocopied that of an autophagic cell. We confirmed hyperactive autophagy in the absence of PTPsigma through use of multiple autophagy markers, as well as electron microscopy. Atg12 and LC3-positive autophagic vesicles were substantially more abundant in the absence of PTPsigma when cells were cultured in full nutrients (constitutive AVs) or treated with rapamycin (induced AVs). These autophagic vesicles accumulated upon treatment with the lysosomal inhibitors, Baf-A1 and chloroquine, demonstrating that they were functional and destined for lysosomal degradation. This phenotype suggests PTPsigma regulates an early step in autophagy induction and its loss results in increased autophagic vesicle generation. This is consistent with the fact that PI(3)P is generated on early phagophores and is required for proper autophagic vesicle formation. A role for PTPsigma in autophagy induction and specifically, PI(3)P regulation, is supported by our findings that PTPsigma localizes to PI(3)P-positive vesicles which increase in number during autophagy.
It remains to be addressed how PTPsigma is targeted to autophagic vesicles. PTPsigma is expressed at the cell surface in a two subunit complex comprised of a large ectodomain and a membrane-spanning intracellular domain. Accordingly, it is implicated in cell-cell and cell-ECM interactions, and it is a critical regulator of axon homeostasis and neuronal development [15] [16] [17] [18] . Relevant to our own work, ectodomain shedding and internalization of a membrane-bound carboxy-terminal fragment has been demonstrated previously [18] . Through immunofluorescent analysis of PTPsigma using D1 domain-specific antibodies, we place intracellular PTPsigma on PI(3)P-positive autophagic vesicles. Autophagosomes frequently fuse with endosomes during their maturation, forming hybrid organelles called amphisomes, establishing the possibility that PTPsigma is internalized by endocytosis to arrive at autophagic vesicles [19] . Further, the close relative of PTPsigma, LAR (PTPRF), undergoes an additional proteolytic event whereby a soluble intracellular domain is formed and targeted inside the cell, similar to the Notch receptor [20] . PTPsigma contains similar cleavage residues to LAR, making it therefore plausible that PTPsigma is targeted from the plasma membrane to autophagic vesicles through a series of proteolytic events in response to autophagic stimuli. Thus, this phosphatase may serve several 8 unique functions during various cellular conditions which are governed by its subcellular localization.
A critical finding presented here is the recruitment of PTPsigma to vesicular structures during amino acid-starvation which occurs even in the absence of PI(3)P generation. This finding, together with the hyperactivation of autophagy elicited by PTPsigma knockdown (as measured by PI(3)P, Atg12, and LC3), suggests PTPsigma regulates autophagy at an early step upstream of this lipid. In further support of this, we found that while almost all PTPsigma-positive vesicles are also positive for PI(3)P (EGFP-2xFYVE presence), fewer harbored LC3, a marker which is incorporated into AVs at later maturation stages.
There are several potential mechanisms by which PTPsigma may function to regulate autophagy. First, it is possible that PTPsigma could directly dephosphorylate PI(3)P following recruitment to AVs. We did test the activity of recombinant PTPsigma in vitro, and while we could not detect PI(3)P-phosphatase activity, it cannot be entirely excluded that PI(3)P does not serve as a direct substrate in vivo (Figure 2.9) . It is also possible that PTPsigma uses its robust protein phosphatase activity to regulate the function of a PI(3)P-modifying enzyme, such as a PI(3)Pphosphatase or a PI(4)-or PI(5)-kinase. Alternatively, PTPsigma could control the activity of Vps34, which contains at least one phosphotyrosine site, or another component within the larger Vps34 complex [21] . Finally, PTPsigma may contribute to the regulation of autophagy at the earliest initiation step, which is executed by a complex of autophagy proteins, namely ULK1 (Atg1) and Atg13. The functional formation of this complex, which permits the generation of the PI(3)P-positive phagophore, was recently found to be tightly regulated by phosphorylation events [22] [23] [24] [25] . The aim of future work will be to determine the precise mechanism by which PTPsigma functions to regulate autophagy.
Finally, we found that PTPsigma was processed from its P-subunit into a putative C-terminal fragment (CTF). This processing occurs under normal growth conditions and results in CTF targeting and turnover in the lysosome. Further, we uncovered evidence that PTPsigma is processed into a fragment smaller than the CTF during starvation-induced autophagy. This fragment does not appear to be targeted to the lysosome and while it is logical to assume it is an ICD, its molecular weight is smaller than that reported for a LAR ICD [26] . PTPsigma does in fact have residues within and just C-terminal to its transmembrane domain that are similar to those in Notch required for gamma-secretase-mediated ICD formation [27] . However, mutation of the analogous residues in LAR did not impair the ability of gamma secretase to generate an ICD so they may not be critical for a PTPsigma-ICD either [26] . If this detected fragment is in fact an ICD, it may be generated through a unique mechanism or from a site downstream of its transmembrane domain, resulting in a smaller size. Regardless, because PTPsigma exerts its inhibitory effect on autophagy in the presence of nutrients, it is likely that the CTF is the fragment relevant to PI(3)P suppression. The fact that the CTF is membrane-bound and turned over in the lysosome supports a model where PTPsigma is processed and internalized from the cell surface as part of the endocytic pathway. It would likely be during this trafficking that PTPsigma resides on PI(3)P-positive endocytic vesicles and likely suppresses VPS34 signaling to impede the maturation of both endosomal and autophagic vesicles. (3) Table 1 The above results were generated following exposure to a panel of chemical compounds (Rapamycin, Chloroquine, Bafilomycin A1, Taxol, Cisplatin, and Etoposide). The doses administered for Rapamycin, Bafilomycin, and Taxol were in the 0-500 nM range while a 0-500 µM range was utilized for Chloroquine, Cisplatin, and Etoposide. In total, nine doses of each drug were tested in these metastatic prostate cancer lines (C42B, LNCaP, PC3, DU145). 48h post treatment, Cell Titer Glo was used as a readout of cell viability. All data was normalized to an untreated control of the appropriate line. SigmaPlot software was used to establish EC 50 doses.
Introduction
In addition to the well-characterized role of phosphatidylinositol-3-phosphate (PtdIns3P) in endocytosis, recent evidence has uncovered a crucial requirement for this lipid in macroautophagy (autophagy) (Axe et al., 2008; Obara et al., 2008a; Petiot et al., 2000) . Autophagy occurs constitutively in nearly all cells to maintain homeostasis, but is further activated in response to stress as a survival or adaptive mechanism. During autophagy, a double-membrane phagophore forms and elongates around portions of cytosol, matures into an enclosed autophagosome, and delivers its contents to the lysosome for degradation (Klionsky, 2007) . Basic biochemical components (i.e. amino acids and fatty acids) are exported from the lysosome and recycled by the cell, representing an energetically favorable alternative to de novo synthesis. In mammalian systems, the lipid kinase Vps34 forms a complex with several proteins, including Vps15, Beclin1, Atg14L, UVRAG and Bif1 to generate PtdIns3P on autophagic vesicles (Itakura et al., 2008; Zhong et al., 2009 ). PtdIns3P then recruits and tethers effector proteins, such as WIPI-1 (Atg18), which are required for proper membrane formation (Obara et al., 2008b; Proikas-Cezanne et al., 2004) . The crucial requirement for PtdIns3P in this process is evidenced by the fact that autophagy is ablated in mutant Vps34 yeast strains and genetic Vps34 knockouts in Drosophila (Juhasz et al., 2008; Kihara et al., 2001) . Despite knowledge of PtdIns3P production, the antagonistic phosphatases that regulate PtdIns3P during autophagy have remained elusive. Two myotubularin-related phosphatases, MTMR3 and MTMR14 ( However, given the complexity of autophagy execution and the number of proteins in the autophagy network, we predict that additional protein phosphatases exist to regulate this process. Accordingly, we performed a high-content cell-based RNAi screen using a fluorescent PtdIns3P sensor to identify protein phosphatases that function upstream of PtdIns3P during autophagy.
Results
RNAi screening identifies PTPs as a modulator of PtdIns3P signaling
FYVE (Fab1, YOTB, Vac1 and EEA1) domains are cysteine-rich zinc-finger binding motifs that specifically recognize and bind PtdIns3P (Gaullier et al., 1998 ). An EGFP molecule fused to two tandem FYVE domains, termed EGFP-2xFYVE, serves as an effective cellular sensor of PtdIns3P (Gillooly et al., 2000) . We analyzed U2OS cells stably expressing this construct by fluorescent microscopy and found that PtdIns3P predominantly localized to punctate, often perinuclear, vesicles when cultured in complete growth medium with full nutrients ( To identify genes that downregulate PtdIns3P signaling, we used several siRNAs targeting over 200 known and putative human phosphatases. The siRNAs were introduced into U2OS EGFP-2xFYVE cells, and the cells were subsequently monitored
Summary
Macroautophagy is a dynamic process whereby portions of the cytosol are encapsulated in double-membrane vesicles and delivered to the lysosome for degradation. Phosphatidylinositol-3-phosphate (PtdIns3P) is concentrated on autophagic vesicles and recruits effector proteins that are crucial for this process. The production of PtdIns3P by the class III phosphatidylinositol 3-kinase Vps34, has been well established; however, protein phosphatases that antagonize this early step in autophagy remain to be identified. To identify such enzymes, we screened human phosphatase genes by RNA interference and found that loss of PTPs, a dual-domain protein tyrosine phosphatase (PTP), increases levels of cellular PtdIns3P. The abundant PtdIns3P-positive vesicles conferred by loss of PTPs strikingly phenocopied those observed in cells starved of amino acids. Accordingly, we discovered that loss of PTPs hyperactivates both constitutive and induced autophagy. Finally, we found that PTPs localizes to PtdIns3P-positive membranes in cells, and this vesicular localization is enhanced during autophagy. We therefore describe a novel role for PTPs and provide insight into the regulation of autophagy. Mechanistic knowledge of this process is crucial for understanding and targeting therapies for several human diseases, including cancer and Alzheimer's disease, in which abnormal autophagy might be pathological.
for PtdIns3P signaling. We identified several genes whose knockdown significantly increased the abundance of cellular EGFP-2xFYVE punctae (Fig. 1E , supplementary material Table  S1 ). Most notably, PtdIns3P was substantially increased following knockdown of the myotubularin family member MTMR6 (supplementary material Fig. S1B ,C), as well as the dual-domain protein tyrosine phosphatase PTPRS (PTPs) (Fig. 1D,E) . Although reduced expression of MTMR6 was characterized by the appearance of enlarged perinuclear vesicles, the siRNAs targeting PTPs caused a dramatic accumulation of abundant smaller vesicles throughout the cytosol, which phenocopied results observed during amino acid starvation (Fig. 1C ,D, supplementary material Movie 3). Quantification of PtdIns3P-positive vesicles revealed a 3.5-fold increase in abundance during starvationinduced autophagy and a nearly 5-fold increase caused by knockdown of PTPs alone (Fig. 1F ). This phenotype was confirmed using four unique siRNA sequences targeting PTPs (supplementary material Fig. S1D -K).
To validate a physiological increase in PtdIns3P following knockdown of PTPs, phospholipids were radiolabeled with [ 32 P]orthophosphate in vivo, extracted, and resolved by thin-layer chromatography. Indeed, PtdIns3P levels were specifically elevated in the absence of PTPs, whereas other lipid species remained unchanged (Fig. 1G) . To determine the identity of the PtdIns3P-positive vesicles formed by knockdown of PTPs, we immunostained cells with well-established markers of early endosomes [anti-EEA1 (early endosomal antigen 1)] and autophagic vesicles (AVs) [anti-LC3 (light chain 3)]. We found that knockdown of PTPs had no substantial effect on the presence of EEA1-positive endosomes (Fig. 1H , supplementary material Fig. S2A ), but significantly increased the abundance of LC3-positive vesicles (Fig. 1I ). From this, we hypothesized that PTPs functions during autophagy and focused our attention on this enzyme as a candidate autophagic phosphatase.
Loss of PTPs hyperactivates constitutive and induced autophagy
The striking resemblance of PtdIns3P-positive vesicles induced by PTPs knockdown to AVs formed during amino acid starvation led us to propose that autophagy is hyperactivated in the absence of PTPs, despite the presence of nutrients. To test this, autophagy was analyzed in U2OS cells by evaluating two ubiquitin-like proteins, Atg12 and LC3 (Atg8), which become conjugated to AVs during autophagy. Following phagophore nucleation, Atg12 covalently binds Atg5 and oligomerizes with Atg16L at the autophagic membrane (Klionsky, 2007) . To measure vesicle abundance at this step, we immunostained cells for endogenous Atg12 and quantified Atg12-positive punctae. We found that 
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knockdown of PTPs increased AV abundance three-or fivefold over the control when cells were cultured with rapamycin, a potent mTOR inhibitor and autophagy inducer, or full nutrients, respectively ( Fig The membrane-bound Atg5-Atg12-Atg16L complex permits lipidation of LC3, which is a classic marker for AVs (Hanada et al., 2007) . LC3 is unique among the autophagy proteins in that a portion of it remains membrane bound and is degraded in the lysosome along with vesicle cargo. Therefore, lysosomal function can be inhibited [i.e. with bafilomycin A1 (Baf-A1) or chloroquine treatment] and LC3 accumulation used as a measure of autophagic flux (Tanida et al., 2005) . We found that both knockdown of PTPs and amino acid starvation increased the abundance of LC3-II, the AV-lipidated form of LC3, when lysates were probed with endogenous antibodies (Fig. 2B) . Similarly, we observed an increased number of EGFP-LC3-positive punctae when PTPs expression was reduced under normal growth conditions, and these structures accumulated substantially when cells were cultured with Baf-A1, indicating their functionality (Fig. 2C-F) . Knockdown of PTPs caused an even greater increase in EGFP-LC3 punctae above the control level when cells were treated with both Baf-A1 and rapamycin (Fig. 2G,H) . Similar results were obtained when AVs were quantified from cells immunostained for endogenous LC3 (supplementary material Fig. S2C ).
To confirm hyperactive autophagy in the absence of PTPs independently of fluorescent markers, we detected AVs by transmission electron microscopy (TEM). AVs are hallmarked by unique double membranes and by the presence of engulfed cytosolic content: features that allow them to be easily detected by TEM. Although control cells contained very few AVs, chloroquine treatment increased their abundance, most of which appeared to be autolysosomal, as expected (Fig. 3A,B) . Similarly, cells deprived of amino acids for 1 hour harbored elevated numbers of doublemembrane AVs, as did cells transfected with siRNAs against PTPs, but cultured in full nutrients (Fig. 3C,D) . To establish this phenotype independently of RNAi, we examined autophagy during PTPs loss using wild-type (Ptprs +/+ ) and PTPs knockout (Ptprs -/-) murine embryonic fibroblasts (MEFs). We have previously generated
Ptprs
-/-mice by inserting a selectable neomycin resistance gene into the D1 phosphatase (catalytic) domain. From these mice, we generated MEFs that lack both Ptprs transcript and protein, as measured by northern blot and western blot, respectively (Elchebly et al., 1999) . TEM analysis showed that both Ptprs +/+ and Ptprs -/-primary MEFs contained a basal level of AVs; however, they were twice as abundant in Ptprs -/-MEFs ( Fig. 3E-G) . Collectively, these results demonstrate that loss of PTPs, by RNAi and genetic deletion, increases both constitutive and induced autophagy.
PTPs localizes to PtdIns3P-positive vesicles and rescues the siRNA phenotype
Given the robust PtdIns3P response elicited by knockdown of PTPs, we hypothesized that PTPs regulates autophagy by functioning at the level of PtdIns3P-positive vesicles. PTPs is a bulky receptor-like PTP with an extracellular segment and two tandem cytosolic phosphatase domains (termed D1 and D2). Complex processing events have been reported for PTPs and related enzymes, including ectodomain shedding and internalization from the cell surface (Aicher et al., 1997; Ruhe et al., 2006) . To determine the localization of PTPs phosphatase domains, untagged full-length protein (FL-PTPs) was transiently expressed in U2OS EGFP-2xFYVE cells and detected by fluorescent microscopy using D1-targeted monoclonal antibodies. We found that in addition to its presence at the plasma membrane, PTPs localized to the perinuclear region and to numerous intracellular-vesicle-like structures, many of which were positive for PtdIns3P (Fig. 4A) . Strikingly, autophagy induction by amino acid starvation induced a redistribution of PTPs to smaller vesicles, which were abundant throughout the cytosol and were almost entirely PtdIns3P positive (Fig. 4B,C) . In support of the notion that this localization was autophagic, we discovered that PTPs was also capable of localizing to mRFP-LC3-positive punctae in the context of both basal and induced autophagy (supplementary material Fig. S3B ).
We further used exogenous PTPs expression in an RNAi rescue experiment to demonstrate the specificity of phenotype induced by PTPRS siRNA. The naturally occurring isoform of PTPs used in our studies lacks the fourth through seventh fibronectin domains (present in the longest isoform): a region encompassing the sequence targeted by a potent siRNA (siRNA-1; see supplementary material Fig. S1E ,J,K) (Pulido et al., 1995) . The accumulation of small, abundant, non-perinuclear PtdIns3P-positive vesicles induced by siRNA transfection was rescued by exogenous expression of PTPs, an effect that was dose dependent (Fig. 4D,E) . This result suggests a target-specific effect of siRNA-mediated knockdown of PTPs and a role for this enzyme in PtdIns3P signaling.
To verify that the PTPs-positive punctate structures were in fact vesicles functioning in a lysosomal pathway, we monitored the localization of PTPs in Baf-A1-treated cells. Baf-A1 prevents maturing vesicles (e.g. endocytic and autophagic) from fusing with lysosomes and in turn, they accumulate in a perinuclear region. We found that PTPs-positive vesicular structures began to accumulate quickly (within 15 minutes) and densely populated the perinuclear region within several hours (Fig. 4F ). This suggests that PTPs normally localizes to vesicles destined for the lysosome.
Finally, to determine whether PTPs functions upstream or downstream of PtdIns3P at the starvation-induced punctae, we analyzed its localization in cells depleted of the phospholipid. Autophagy was induced by amino acid starvation in cells treated with wortmannin, a potent and irreversible inhibitor of Vps34 and other phosphoinositide 3-kinase isoforms, or vehicle (DMSO). In vehicle-treated cells, starvation induced the formation of abundant PtdIns3P-positive vesicles, which also contained PTPs (Fig. 5A) . Conversely, wortmannin treatment essentially ablated the formation of PtdIns3P during starvation; however, PTPs was still recruited to the abundant punctate structures (Fig. 5B ). This finding suggests that the localization of PTPs to intracellular structures formed during autophagy occurs upstream, or independently, of PtdIns3P.
PTPs regulates autophagy
Discussion
Using a high-content cell-based RNAi screen, we have identified phosphatases whose knockdown elevates cellular PtdIns3P. Notably, RNAi-mediated knockdown of MTMR6 and several other phosphatases resulted in swollen and often perinuclear PtdIns3P-positive vesicles. Previous studies have shown similar phenotypes when endocytic PtdIns3P is elevated, for example, by constitutive activation of early endosomal Rab5, or knockdown of the phosphatidylinositol 5-kinase PIKfyve (Murray et al., 2002; Rutherford et al., 2006) . Accordingly, the vesicles observed following knockdown of these phosphatases are probably endosomal, and these enzymes, including MTMR6, might function in endocytic signaling. Of note, knockdown of both PTPN11 (SHP2) and PTPN13 (PTPL1) resulted in increased numbers of EGFP-2xFYVE punctae (supplementary material Table S1 ). PTPN13, a phosphatase that is proposed to have both tumor suppressive and oncogenic functions, has been implicated in several signal transduction pathways. Specifically, PTPN13 was shown to inhibit PI3K/Akt signaling and thus, the PtdIns3P phenotype elicited by knockdown could potentially be explained by altered 3Ј-phosphoinositide metabolism Dromard et al., 2007) . Mutations in SHP2 are associated with several human diseases, most notably Noonan syndrome, LEOPARD syndrome and juvenile myelomonocytic leukemia Kontaridis et al., 2006; Mohi and Neel, 2007; Mohi et al., 2005) . Its activity has been linked to numerous signaling pathways, often downstream of receptor tyrosine kinases, and the observed phenotype could be a consequence of disruption of any number of substrates . Surprisingly, we did not identify MTMR3 or MTMR14 (hJumpy), the PtdIns3P phosphatases with reported roles in autophagy. The myotubularin phosphatases comprise a large, highly 
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conserved family of enzymes whose members have been shown to function as heteromeric partners (Lorenzo et al., 2006) . As one example, MTMR3 and MTMR4, both FYVE-domain containing phosphatases, have been demonstrated to interact with one another and inhibit PtdIns3P (Lorenzo et al., 2006) . Accordingly, gene-bygene loss-of-function analysis of this family might not reveal phenotypes if compensation within the family occurs. Furthermore, these enzymes may serve cell-or context-specific functions that are not revealed in this study.
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Journal of Cell Science 124 (5) The most striking result from this study was the presence of abundant PtdIns3P-positive vesicles following knockdown of PTPs, which phenocopied that of an autophagic cell. We confirmed hyperactive autophagy in the absence of PTPs through the use of several autophagy markers, as well as electron microscopy. Atg12-and LC3-positive autophagic vesicles were substantially more abundant in the absence of PTPs when cells were cultured in full nutrients (constitutive AVs) or treated with rapamycin (induced AVs). These autophagic vesicles accumulated upon treatment with the lysosomal inhibitors, Baf-A1 and chloroquine, demonstrating that they were functional and destined for lysosomal degradation. This phenotype suggests that PTPs regulates an early step in autophagy induction, and its loss results in increased autophagic vesicle generation. This is consistent with the fact that PtdIns3P is generated on early phagophores and is required for proper autophagic vesicle formation. A role for PTPs in autophagy induction and more specifically in PtdIns3P regulation, is supported by our findings that PTPs localizes to PtdIns3P-positive vesicles that increase in number during autophagy.
It remains to be addressed how PTPs is targeted to autophagic vesicles. PTPs is expressed at the cell surface in a two-subunit complex comprised of a large ectodomain and a membranespanning intracellular domain. Accordingly, it is implicated in cellcell and cell-ECM interactions, and it is a crucial regulator of axon homeostasis and neuronal development (Aicher et al., 1997; Elchebly et al., 1999; Uetani et al., 2006; Wallace et al., 1999) . Relevant to our own work, ectodomain shedding and internalization of a membrane-bound C-terminal fragment has been demonstrated previously (Aicher et al., 1997) . Through immunofluorescence analysis of PTPs using D1-domain-specific antibodies, we place intracellular PTPs on PtdIns3P-positive autophagic vesicles. Autophagosomes frequently fuse with endosomes during their maturation, forming hybrid organelles called amphisomes, establishing the possibility that PTPs is internalized by endocytosis to arrive at autophagic vesicles (Klionsky, 2007) . Furthermore, the close relative of PTPs LAR (PTPRF), undergoes an additional proteolytic event whereby a soluble intracellular domain is formed and targeted inside the cell, similarly to the Notch receptor (Ruhe et al., 2006) . PTPs contains similar cleavage residues to LAR, making it therefore plausible that PTPs is targeted from the plasma membrane to autophagic vesicles through a series of proteolytic events in response to autophagic stimuli. Thus, this phosphatase might serve several unique functions during various cellular conditions that are governed by its subcellular localization.
An important finding presented here is the recruitment of PTPs to vesicular structures during amino acid starvation, which occurs even in the absence of PtdIns3P generation. This finding, together with the hyperactivation of autophagy elicited by knockdown of PTPs (as measured by PtdIns3P, Atg12 and LC3), suggests that PTPs regulates autophagy at an early step upstream of this lipid. In further support of this, we found that although almost all PTPspositive vesicles are also positive for PtdIns3P (EGFP-2xFYVE presence), fewer harbored LC3, a marker that is incorporated into AVs at later stages of maturation.
There are several potential mechanisms by which PTPs might function to regulate autophagy. First, it is possible that PTPs directly dephosphorylates PtdIns3P following recruitment to AVs. We tested the activity of recombinant PTPs in vitro, and although we could not detect PtdIns3P phosphatase activity, it cannot be entirely excluded that PtdIns3P does not serve as a direct substrate in vivo (supplementary material Fig. S4) . It is also possible that PTPs uses its robust protein phosphatase activity to regulate the function of a PtdIns3P-modifying enzyme, such as a PtdIns3P phosphatase or a phosphoinositide 4-or 5-kinase. Alternatively, PTPs could control the activity of Vps34, which contains at least one phosphotyrosine site, or another component within the larger Vps34 complex (Imami et al., 2008) . Finally, PTPs might contribute to the regulation of autophagy at the earliest initiation step, which is executed by a complex of autophagy proteins, namely ULK1 (Atg1) and Atg13. The functional formation of this complex, which permits the generation of the PtdIns3P-positive phagophore, was recently found to be tightly regulated by phosphorylation events (Chang and Neufeld, 2009; Ganley et al., 2009; Hosokawa et al., 2009; Jung et al., 2009 ). The aim of future work will be to determine the precise mechanism by which PTPs functions to regulate autophagy.
Materials and Methods
siRNA screen and validation
U2OS EGFP-2xFYVE cells were seeded on 96-well plates (2000 cells per well) in McCoy's 5A medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS, Invitrogen) at 37°C for 24 hours. Four siRNA molecules per phosphatase gene (phosphatase siRNA library version 2.0, Qiagen, Valencia, CA) were transfected per well at a final concentration of 25 nM using 0.2 l HiPerfect transfection reagent (Qiagen) per well. After 48 hours, cells were fixed with 3.7% formaldehyde and nuclei were stained with Hoechst 33342 (Invitrogen). Cells were visualized at 40ϫ magnification on a Zeiss LSM 510 Meta confocal microscope (Oberkochen, Germany) and EGFP-2xFYVE fluorescence was compared with that of control siRNA transfected cells within each plate. Triplicate wells from each gene were qualitatively scored by two independent scorers on a scale from -100 (decreased EGFP-2xFYVE signal and distribution) to +100 (increased) and mean scores were determined. Twenty-seven phosphatase genes whose knockdown increased EGFP-2xFYVE fluorescence in the primary screen were used in a secondary screen, where four siRNAs were individually transfected to eliminate off-target hits. The primary score was multiplied by a binned secondary screen score (score of 1.0 for 3/4 or 4/4 siRNAs yielding a phenotype; 0.75 for 2/4 siRNAs; and 0 for 0/4 or 1/4 siRNAs). Quantitative real-time PCR (qRT-PCR) assays with SYBR green dye (Roche, Basel, Switzerland) and gene-specific primers confirmed that siRNAs effectively reduced mRNA expression of target genes. For imaging, cells were cultured on number 1.5 coverglass, transfections repeated as above, cells fixed, nuclei stained, and coverglass inverted into microslides with mounting gel. A control siRNA transfected well was cultured for 3 hours in amino acid starvation medium [Dulbecco's phosphate-buffered saline (DPBS) with 10% FBS and 1 g/l D-glucose]. Cells were imaged using a 60ϫ oil objective on a Nikon TE300 fluorescent microscope (Tokyo, Japan). EGFP-2xFYVE-positive vesicles were quantified using image analysis software.
Phospholipid labeling, extraction and thin-layer chromatography
U2OS cells were seeded in McCoy's 5A with 10% FBS at 200,000 cells per well of six-well tissue culture plates. After 24 hours, control or PTPRS siRNAs were transfected at a final concentration of 25 nM using 2 l HiPerfect transfection reagent per ml medium. Control siRNA was All-star Negative Control (Qiagen) and PTPRS siRNAs were two unique sequences (SI02759288, SI03056284, Qiagen). After 48 hours of transfection, the medium was replaced with phosphate-free DMEM (Invitrogen) supplemented with 10% phosphate-free FBS for 30 minutes. [ 32 P]O 4 (0.25 mCi) was added per ml of medium for an additional 2 hours (Perkin Elmer, Waltham, MA). Radiolabeling was quenched with ice-cold TCA (10% final concentration) and cells incubated on ice for 1 hour. Cells were scraped, pelleted and lipids extracted via an acidified Bligh and Dyer method (Bird, 1994) . Lipids were lyophilized, resuspended in chloroform:methanol (1:1), spotted on 20 cm ϫ 20 cm silica gel TLC plates (Whatman, Maidstone, UK), and resolved in a chamber using boric acid buffer (Walsh et al., 1991) . A PtdIns3P standard was generated by incubating synthetic phosphatidylinositol (diC16 PtdIns; Echelon, Salt Lake City, UT) with immunoprecipitated PI3K (using anti-p85, Cell Signaling, Danvers, MA) and [ 32 P]ATP (Perkin Elmer). The TLC plate was exposed to film for 20 hours at -80°C and developed.
Fluorescent microscopy and western blot analyses of autophagy markers
U2OS cells were seeded at a density of 35,000 cells per well in McCoy's 5A medium with 10% FBS on number 1.5 coverglasses in 24-well tissue culture plates (for fluorescent imaging) or 150,000 cells per well on six-well dishes (for western blot). After 24 hours, cells were transfected with control or PTPRS siRNAs for 48 hours, as described above. Following, cells were treated for 1-2 hours in amino acid starvation medium or with 50 nM rapamycin (Calbiochem, San Diego, CA), 25 M chloroquine (Sigma, St Louis, MO), 100 nM Baf-A1 (A.G. Scientific, San Diego, CA) or normal growth medium (full nutrients; McCoy's 5A with 10% FBS), as indicated. For western blots, cells were lysed [in 10 mM KPO 4 , 1 mM EDTA, 10 mM MgCl 2 , 5 mM EGTA, 50 mM bis-glycerophosphate, 0.5% NP40, 0.1% Brij35, 0.1% sodium deoxycholate, 1 mM NaVO 4 , 5 mM NaF, 2 mM DTT, and complete protease inhibitors (Sigma)] and 20 g of total protein was resolved by SDS-PAGE. Proteins were transferred to PVDF membranes and probed with primary antibodies (LC3B, Cell Signaling Technologies; anti--tubulin, Sigma) for 16 hours at 4°C followed by secondary antibodies (HRP-linked rabbit or mouse IgG, GE, Piscataway, NJ) for 1 hour at room temperature. Proteins were detected by enhanced chemiluminescence. For EGFP-LC3 imaging, U2OS cells stably expressing ptfLC3 (Addgene plasmid 21074) (Kimura et al., 2007) were fixed with 3.7% formaldehyde and nuclei stained with Hoechst 33342 (2 g/ml). Coverglasses were inverted onto Journal of Cell Science microslides using mounting gel and cells imaged using a 100ϫ oil-immersion objective on a Nikon Eclipse Ti fluorescence microscope. For immunofluorescence, cells were fixed with 3.7% formaldehyde, permeabilized with 0.2% Triton-X 100, and blocked with 3% bovine serum albumin (BSA) in PBS. Antibodies (LC3B, ATG12, EEA1; Cell Signaling Technologies) were added for 16 hours at 4°C followed by Alexa-Fluor-488-conjugated anti-rabbit IgG (Invitrogen) for 1 hour at room temperature. Nuclei were counterstained with Hoechst 33342, coverglasses were inverted onto microslides using mounting gel and cells were imaged using 60ϫ or 100ϫ oil-immersion objectives on a Nikon TE300 fluorescence microscope (LC3, ATG12) or a 63ϫ water-immersion objective on a Zeiss LSM510 Meta confocal microscope (EEA1). For quantification, punctae were counted using image analysis software after establishing an intensity threshold.
Transmission electron microscopy
U2OS cells in 10 cm dishes were transfected with control or PTPRS siRNAs for 48 hours as described above. Cells were briefly trypsinized, pelleted, rinsed and resuspended in 2% glutaraldehyde fixative (Sigma). Cell pellets were embedded in 2% agarose, postfixed in osmium tetroxide, and dehydrated with an acetone series. Samples were infiltrated and embedded in Poly/Bed 812 resin and polymerized at 60°C for 24 hours. Ultrathin sections (70 nm) were generated with a Power Tome XL (Boeckeler Instruments, Tucson, Arizona) and placed on copper grids. Cells were examined using a JEOL 100Cϫ Transmission Electron Microscope at 100 kV (Tokyo, Japan). Autophagic structures were quantified from images encompassing approximately 8.5 m 2 of cell area each. Electron microscopy services were performed by the Michigan State University Center for Advanced Microscopy (East Lansing, MI).
Exogenous PTPs expression and immunofluorescence
U2OS EGFP-2xFYVE cells were seeded at a density of 20,000 cells per well in McCoy's 5A medium with 10% FBS on number 1.5 coverglasses in 24-well tissue culture dishes. Full-length PTPRS cDNA (BC104812) was inserted into pRK7 by EcoRI digestion and ligation to yield FL-PTPs-pRK7 (FL-PTPs). DNA was transfected at 0.15 g per well using 0.45 l FuGeneHD transfection reagent (Roche, Mannheim, Germany) in 50 l Optimem and 450 l McCoy's 5A with 10% FBS for 24 hours. For 2 hours, cells were cultured with full nutrient medium or starved of amino acids (Fig. 4A-C) , or amino acid starved while treated with DMSO or 100 nM wortmannin (Sigma) (Fig. 5, supplementary material Fig. S3 ). Alternatively, cells were treated with Baf-A1 (100 nM in full nutrient medium) for 0, 15, 60 or 240 minutes (Fig. 4E ). Cells were then fixed with 3.7% formaldehyde, permeabilized with 0.2% Triton X-100, blocked in 3% BSA, and stained with antibodies targeting the D1 domain of PTPs for 2 hours at room temperature. AF-546-conjugated antimouse-IgG (Invitrogen) were incubated for an additional hour at room temperature and nuclei were stained with Hoechst 33342. Cells were imaged using oil-immersion objectives at 60ϫ on a Nikon TE3000 or 100ϫ on an Eclipse Ti fluorescent microscope. For Fig. 4C , cells were treated as above and imaged using a 63ϫ waterimmersion objective on a Zeiss LSM510 Meta microscope. Red (AF-546, FL-PTPs) and green (EGFP-2xFYVE, PtdIns3P) channels were captured with confocality through the Z-plane using 16 increments of 0.25 m. Stacks through the indicated X and Y planes are shown at the border of an image of the third Z-plane. For supplementary material Fig. S3B , U2OS cells stably expressing mRFP-LC3 (Addgene plasmid 21075) (Kimura et al., 2007) were seeded, transfected, treated (full nutrient or amino acid starvation media for 2 hours), and stained as above. Images were captured at 100ϫ using an oil-immersion objective on an Eclipse Ti fluorescent microscope.
Rescue of siRNA phenotype
U2OS EGFP-2xFYVE cells were seeded on number 1.5 coverglasses in 24-well dishes at 20,000 cells per well in McCoy's 5A medium with 10% FBS. 24 hours later, PTPRS siRNA-1 (CACGGCATCAGGCGTGCACAA; Qiagen) was transfected at a concentration of 25 nM using 1 l oligofectamine per well per 500 l McCoy's with 10% FBS (Invitrogen). FL-PTPs-pRK7 plasmid DNA was transfected 24 hours later at a concentration of 0.15 g DNA per well using 0.45 l FuGeneHD transfection reagent in 50 l Optimem and 450 l McCoy's 5A with 10% FBS for an additional 24 hours. Cells were fixed and immunostained as described above. Cells were imaged using a 60ϫ oil objective on a Nikon TE300 fluorescent microscope for EGFP-2xFYVE phenotype (green) and FL-PTPs-pRK7 expression (red). FL-PTPspRK7 expression levels were categorized as high or low. The presence or absence of a robust PTPRS siRNA-induced EGFP-2xFYVE phenotype was determined (phenotype defined as the presence of small, abundant, non-perinuclear EGFP2xFYVE-positive vesicles; indicated with white arrows in Fig. 4D ) for 30-40 cells each of low and high FL-PTPs-expressing cells, as well as cells transfected with PTPRS siRNA-1 but not FL-PTPs-pRK7.
In vitro phosphatase assays
GST-tagged recombinant PTPs containing all residues C-terminal to the transmembrane domain (BC104812 cDNA; aa 883-1501) was generated in pGEXKG (Guan and Dixon, 1991) . GST-tagged full-length MTMR6 (NM_004685.2) was generated in pGEXKG and GST-tagged recombinant PTP1B was purchased (Upstate, Billerica, MA). Proteins were purified from BL21 Escherichia coli after isopropyl b-D-1-thiogalactopyranoside (IPTG) induction and used in phosphatase assays. For PtdIns3P phosphatase reactions, 1 g protein was suspended in 50 l assay buffer (50 mM sodium acetate, 25 mM Tris-HCl, 10 mM DTT, pH 6.5) with 0, 25, 50 or 200 M diC8-PtdIns3P and reactions carried out at 37°C for 25 minutes. For Tyr-P phosphatase assays, reactions were carried out as above using 0, 10, 25 or 100 M Tyr-P peptide (TSTEPQpYQPGENL; Upstate) at 37°C for 15 minutes. Released phosphates were detected with malachite green (Upstate) and absorbance measured at 650 nm. Background levels from enzyme-only and substrate-only (Tyr-P or PtdIns3P) reactions were subtracted and absorbance converted to picomoles free phosphate released per minute using a standard curve.
We thank the Van Andel Institute Systems Biology lab for advice, analysis, and reagents. 1H ). EEA1-positive vesicles were quantified using image analysis software. Bars represent s.e.m. (B) U2OS cells transfected with control (left panels) or PTPRS (right panels) siRNAs were cultured for 1 hour with nutrient-rich medium (top panels) or 50 nM rapamycin (bottom panels). Cells were stained with anti-ATG12 antibodies and imaged by fluorescent microscopy at 60x (green: ATG12; blue: nuclei). Bars, 10 µm. (C) U2OS cells transfected with control or PTPRS siRNAs were cultured for 1 hour with normal growth media (full nutrients; left), 25 μM chloroquine in normal growth media (middle), or 50 nM rapamycin and 25 μM chloroquine in normal growth media (right). Cells were fixed, immunostained with anti-LC3B antibodies, and imaged by fluorescent microscopy at 60x. LC3-positive punctae were quantified images using image analysis software (black: control siRNA; white: PTPRS siRNAs). Bars represent s.e.m., *p < 0.05, **p < 0.01. Table S1 . siRNA-mediated knockdown of human phosphatase genes alters cellular PI(3)P. U2OS-EGFP-2xFYVE cells were transfected with siRNAs targeting human phosphatase genes for 48 h (4 siRNA sequences per gene per well; all four sequences displayed). Following knockdown, EGFP-2xFYVE signal and distribution was visualized by confocal microscopy and scored from -100 (decreased punctae from control cells) to +100 (increased punctae) and means determined. Select genes were validated using multiple unique siRNA sequences and their efficacy was incorporated into their scores (see Methods). Genes were ranked based on their scores from 1 (most increased EGFP-2xFYVE) to 206 (most decreased).
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